Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.78 |
| ▸ | TSHR | P16473 | 5/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289622 | 0.85 | KDM4E (0.64) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1459701 | 0.84 | GPR119 (0.79) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL30516861 | 0.84 | GPR119 (0.79) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL4550239 | 0.83 | ALDH1A1 (0.76) | HSD17B10TSHRCYP3A4ALDH1A1KDM4E | |
| SCHEMBL22092825 | 0.82 | HSD17B10 (0.81) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL27580597 | 0.82 | ALDH1A1 (0.82) | HSD17B10TSHRCYP3A4ALDH1A1KDM4E | |
| SCHEMBL14413281 | 0.82 | KDM4E (0.70) | HSD17B10TSHRALDH1A1KDM4EUSP2 | |
| SCHEMBL5235991 | 0.82 | KDM4E (0.57) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL390463 | 0.81 | GPR119 (0.57) | HSD17B10TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL1459007 | 0.81 | ALDH1A1 (0.68) | HSD17B10TSHRCYP3A4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020123872-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | HSD17B10 218/4885TSHR 4037/4885CYP2D6 381/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | HSD17B10 218/4885TSHR 4037/4885CYP2D6 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.